For this phase 2 , randomised , placebo-controlled , clinical trial , we enrolled patients with recent-onset type 1 diabetes , aged 12-35 years , and with a peak C-peptide of 0.4 nM or greater on mixed meal tolerance test from 11 sites in the USA .